We are live on ! Find out more
NRIX icon

Nurix Therapeutics
NRIX

101 hedge funds and large institutions have $1.28B invested in Nurix Therapeutics in 2021 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 39 increasing their positions, 10 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

660% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 5

290% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 10

49% more funds holding

Funds holding: 68 → 101 (+33)

33% more funds holding in top 10

Funds holding in top 10: 6 → 8 (+2)

18% more capital invested

Capital invested by funds: $1.09B → $1.28B (+$196M)

8.01% more ownership

Funds ownership: 85.28% → 93.29% (+8%)

67% less call options, than puts

Call options by funds: $6K | Put options by funds: $18K

Holders
101
Holders Change
+33
Holders Change %
+48.53%
% of All Funds
1.77%
Holding in Top 10
8
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+33.33%
% of All Funds
0.14%
New
38
Increased
39
Reduced
10
Closed
5
Calls
$6K
Puts
$18K
Net Calls
-$12K
Net Calls Change
-$12K

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$94.7M
2
WA
Wasatch Advisors
Utah
+$39.2M
3
State Street
State Street
Massachusetts
+$35.1M
4
Jennison Associates
Jennison Associates
New York
+$27.3M
5
BBA
Baker Bros. Advisors
New York
+$25.2M

Top Sellers

1
FCMI
Foresite Capital Management IV
California
-$42M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$41.1M
3
TGI
TRV GP III
Massachusetts
-$34.6M
4
LGM
Logos Global Management
California
-$7.57M
5
WP
Woodline Partners
California
-$5.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
CG
1
Column Group
California
$167M – – –
TGI
2
TRV GP III
Massachusetts
$140M -$34.6M -914,216 -17%
RG
3
Redmile Group
California
$103M +$17.7M +467,992 +16%
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$96.2M +$94.7M +2,502,069 +423%
BBA
5
Baker Bros. Advisors
New York
$76.3M +$25.2M +665,161 +37%
EC
6
EcoR1 Capital
California
$62.8M +$18M +475,000 +31%
BlackRock
7
BlackRock
New York
$56.5M +$24.5M +646,715 +55%
State Street
8
State Street
Massachusetts
$42.8M +$35.1M +926,630 +205%
Wellington Management Group
9
Wellington Management Group
Massachusetts
$42.3M -$41.1M -1,087,158 -44%
BCLSI
10
Bain Capital Life Sciences Investors
Massachusetts
$39.9M – – –
FCMI
11
Foresite Capital Management IV
California
$38.5M -$42M -1,109,348 -47%
BC
12
Boxer Capital
California
$38.1M – – –
EAM
13
Eventide Asset Management
Massachusetts
$37.3M +$5.68M +150,000 +14%
Vanguard Group
14
Vanguard Group
Pennsylvania
$36.2M +$20.6M +544,999 +88%
WA
15
Wasatch Advisors
Utah
$32.2M +$39.2M +1,035,701 New
Jennison Associates
16
Jennison Associates
New York
$28.6M +$27.3M +721,743 +364%
PIM
17
Ponoi II Management
California
$21.3M – – –
PM
18
Ponoi Management
California
$21.3M – – –
Fidelity Investments
19
Fidelity Investments
Massachusetts
$18M +$9.21M +243,400 +73%
FCMV
20
Foresite Capital Management V
California
$14M – – –
PAMU
21
Pictet Asset Management (UK)
United Kingdom
$12.4M +$15.1M +399,396 New
Goldman Sachs
22
Goldman Sachs
New York
$10.8M +$7.1M +187,544 +118%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$10.1M +$4.7M +124,287 +62%
HMC
24
Harvard Management Company
Massachusetts
$9.79M – – –
RSCM
25
Rock Springs Capital Management
Maryland
$9.67M +$2.03M +53,700 +21%
1
2 3 4 5

NRIX Hedge Fund Activity: Q1 2021 in Review

101 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q1 2021, worth a combined $1.28B — up 18% from $1.09B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new NRIX positions and 5 closed out — a net gain of 33 holders — while 39 added to existing stakes and 10 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $94.7M. The largest seller was Foresite Capital Management IV, cutting an estimated $42M.

  • 101 institutional investors held Nurix Therapeutics (NRIX) as of Q1 2021, up from 68 in Q4 2020.
  • Funds reported $1.28B of Nurix Therapeutics stock for Q1 2021, up 18% quarter-over-quarter.
  • 38 funds opened new Nurix Therapeutics positions in Q1 2021 and 5 closed out, a net change of +33 holders.
  • The largest Nurix Therapeutics buyer in Q1 2021 was T. Rowe Price Associates, an estimated $94.7M added.
  • The largest Nurix Therapeutics seller in Q1 2021 was Foresite Capital Management IV, an estimated $42M sold.

Based on aggregated 13F filings for Q1 2021.